Key Highlights

  • Company plans IND and/or CTA submission for PM647 in Q3 2026
  • Clinical data readout targeted for 2027
  • Filing follows arbitration win resolving dispute with Beam Therapeutics
  • Preclinical models showed restored functional M-AAT protein levels
  • Liver-targeted LNP delivery system underpins gene-correction approach

With legal uncertainty now resolved following its arbitration victory over Beam Therapeutics, Prime Medicine is shifting focus to the regulatory milestones needed to bring PM647 into human clinical testing. The company confirmed plans to submit an investigational new drug application and/or clinical trial application in the third quarter of 2026, setting up a targeted clinical data readout in 2027 for its Alpha-1 Antitrypsin Deficiency program.

PM647 represents an application of prime editing — a precision gene-correction technology capable of directly rewriting disease-causing mutations rather than merely silencing or replacing genes — aimed at the SERPINA1 mutation responsible for Alpha-1 Antitrypsin Deficiency. The condition results in insufficient production of a protein that normally protects the lungs and liver from enzymatic damage, leaving patients vulnerable to progressive organ deterioration if the deficiency goes uncorrected over time.

Central to the therapy's design is a proprietary liver-targeted lipid nanoparticle delivery system, engineered to direct the prime-editing machinery specifically to hepatocytes, where the SERPINA1 gene is expressed. In preclinical humanized models, this approach successfully restored physiologic levels of functional M-AAT protein — the therapeutic goal of the program — providing an encouraging signal ahead of the planned regulatory filing, though preclinical models do not guarantee equivalent results in actual patients.

The path to this filing was complicated by the now-resolved dispute with Beam Therapeutics, Prime's collaboration partner, over whether PM647 fell within Prime's exclusive therapeutic field. With that question settled decisively in Prime's favor via binding arbitration, the company can now dedicate full attention to the practical work of IND-enabling studies and regulatory submission preparation, setting up 2026 as a pivotal year bridging preclinical validation and the company's first clinical data in this indication.

When does Prime Medicine plan to file for clinical trials of PM647?

The company plans to submit an IND and/or CTA in the third quarter of 2026, with a targeted clinical data readout in 2027.

How does PM647's delivery system work?

PM647 uses a proprietary liver-targeted lipid nanoparticle system to deliver prime-editing machinery directly to hepatocytes, correcting the SERPINA1 gene mutation at its source.

This article is for informational purposes and does not constitute investment advice.